Neurocrine Biosciences. has filed a patent for compounds that modulate the activity of G-protein coupled receptor 52 (GPR52) for the treatment or prevention of neurological diseases and related conditions. The patent claims a compound of Formula (I). GlobalData’s report on Neurocrine Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Neurocrine Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Neurocrine Biosciences's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230234925A1) describes a compound of Formula (I) and its various derivatives. The compound can have different configurations, with X, Y1, and Y2 being CH and Z being N, or Z, Y1, and Y2 being CH and X being N, or X, Y1, and Z being CH and Y2 being N. The patent also mentions that X and Y1 can each be N or CH. The compound can further have R2 and R3 as hydrogen. Additionally, the patent discusses the presence of Q1 as CR4, where R4 is hydrogen, and R7 is hydrogen. Q2 can be CR5, where R5 is halogen, -(CH2)n-CN, C1-C3alkyl, haloC1-C3alkyl, -ORB, or -S(O)mRB. R6 can be halogen, haloC1-C6alkyl, -(CH2)n-CN, unsubstituted C1-C6alkyl, C1-C6alkyl substituted by hydroxyl or nitro, or hydrogen. R5 and R6 can also be -NHC(=O)RB, -ORB, -S(O)mRB, or -S(O)pN(RBRC). The patent further mentions the presence of Z1 and R8, which can have various configurations. R9 can be hydrogen, halogen, C1-C6alkyl, haloC1-C6alkyl, -ORE, -C(=O)RD, or -(CH2)nC(=O)N(RERF). The patent also includes a pharmaceutical composition comprising the compound or its pharmaceutically acceptable salt, along with excipients. Additionally, a method of treating neurological disorders, such as schizophrenia, cognitive impairment, Parkinson's disease, bipolar disorder, and others, by administering the compound or its salt to a subject in need is described in the patent.
In summary, the patent describes a compound of Formula (I) and its derivatives, along with their various configurations and substituents. The compound and its pharmaceutically acceptable salt can be used in the treatment of neurological disorders, including schizophrenia, cognitive impairment, Parkinson's disease, bipolar disorder, and others. The patent also includes a pharmaceutical composition comprising the compound or its salt, along with excipients. This patent provides valuable information for researchers and pharmaceutical companies working in the field of neurological disorders, offering potential new treatment options for these conditions.
To know more about GlobalData’s detailed insights on Neurocrine Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
